We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+65.27%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.03B
AUM Growth
+$1.32B
Cap. Flow
-$125M
Cap. Flow %
-2.48%
Top 10 Hldgs %
53.64%
Holding
139
New
31
Increased
25
Reduced
19
Closed
25

Top Buys

Rank Stock Value
1
KRRO icon
Korro Bio
KRRO
+$47.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$34M
3
ANAB icon
AnaptysBio
ANAB
+$23.6M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$20.7M
5
ZGNX
Zogenix, Inc.
ZGNX
+$20.4M

Top Sells

Rank Stock Value
1
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$104M
2
SLDB icon
Solid Biosciences
SLDB
+$69.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$46.8M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$36.4M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$33.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.17%
2 Financials 0.38%
3 Technology 0.12%
4 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
101
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$523K 0.01%
+6,944
New +$304K
NTRA icon
102
Natera
NTRA
$36.4B
$490K 0.01%
14,549
– –
KRMD icon
103
KORU Medical Systems
KRMD
$187M
$489K 0.01%
+74,813
New +$365K
ACAD icon
104
Acadia Pharmaceuticals
ACAD
$4.51B
$482K 0.01%
+11,256
New +$490K
ARAV
105
DELISTED
Aravive, Inc. Common Stock
ARAV
$450K 0.01%
+32,895
New +$291K
CNST
106
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$283K 0.01%
+6,000
New +$173K
TARA icon
107
Protara Therapeutics
TARA
$214M
$140K ﹤0.01%
+8,544
New +$98K
AVDL
108
DELISTED
Avadel Pharmaceuticals
AVDL
$66K ﹤0.01%
+8,681
New +$45.9K
OTLKW
109
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$33K ﹤0.01%
420,875
– –
ACET icon
110
Adicet Bio
ACET
$77.6M
$14K ﹤0.01%
+83
New +$42K
ONC
111
PUT
BeOne Medicines Ltd
ONC
$33.9B
$4K ﹤0.01%
200,000
-200,000
-50% -$33.2M
ALLK
112
DELISTED
Allakos
ALLK
– –
-6,444
Closed -$507K
AXSM icon
113
Axsome Therapeutics
AXSM
$11.7B
– –
-53,879
Closed -$1.09M
BMRN icon
114
PUT
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-200,000
Closed -$750K
MEDP icon
115
Medpace
MEDP
$16.3B
– –
-6,328
Closed -$532K
LITS
116
Lite Strategy Inc
LITS
$32.4M
– –
-220,022
Closed -$7.39M
MMSI icon
117
Merit Medical Systems
MMSI
$4.82B
– –
-528,788
Closed -$16.1M
MRKR icon
118
Marker Therapeutics
MRKR
$18.5M
– –
-200,000
Closed -$10.2M
SLDB icon
119
Solid Biosciences
SLDB
$792M
– –
-449,987
Closed -$69.8M
GTHX
120
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-15,702
Closed -$358K
CBAY
121
DELISTED
Cymabay Therapeutics
CBAY
– –
-1,520,355
Closed -$7.78M
ORTX
122
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-52,180
Closed -$6.2M
MRTX
123
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-100,000
Closed -$145K
SGEN
124
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-17,000
Closed -$1.45M
CFMS
125
DELISTED
Conformis, Inc. Common Stock
CFMS
– –
-2,000
Closed -$93K
2 3 4
5
6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, Perceptive Advisors held 139 positions worth $5.03B, up 36% from $3.71B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors's Q4 2019 filing shows 31 new, 25 increased, 19 reduced and 25 closed positions. Its largest new stake was Korro Bio: 60,686 shares worth $49.8M. The largest sale was Dova Pharmaceuticals, Inc. Common Stock, an estimated $104M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Financials and Technology.

  • Perceptive Advisors's largest Q4 2019 buy was Korro Bio: 60,686 shares worth $49.8M.
  • Perceptive Advisors added most to Quotient Limited Ordinary Shares in Q4 2019, an estimated $20.7M increase.
  • Perceptive Advisors's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $46.8M.
  • Perceptive Advisors fully exited Dova Pharmaceuticals, Inc. Common Stock in Q4 2019, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $5.03B portfolio in Q4 2019.
  • Perceptive Advisors opened 31 new positions and closed 25 in Q4 2019.
  • Perceptive Advisors's portfolio value rose 36% quarter-over-quarter to $5.03B.

Based on Perceptive Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.